Latest Regulatory Scrutiny News

Manuka Resources’ Taranaki VTM Project has advanced through a critical regulatory checkpoint, with no competing applications or appeals standing in its way, moving closer to expert panel determination.

Chorus Limited’s 2024 fibre regulatory report reveals a stable $5.9 billion asset base and revenue close to the maximum allowed, with a $153.5 million wash-up balance carried forward.

Wellnex Life Limited has had its trading suspension lifted following its response to ASX queries related to a recent shareholder letter, reopening market access to its shares.

The ACCC has issued a preliminary Statement of Issues regarding Elders Limited’s proposed acquisition of Delta Agribusiness, signaling potential competition challenges that could affect the deal’s timeline.

The Takeovers Panel has imposed interim restrictions on shares issued in Emu NL's recent placement, halting any trading by subscribers pending further review.

Inoviq Ltd’s shares have been suspended from trading on the ASX following a price query response, with the suspension to remain until the company meets listing rule requirements.

REA Group has confirmed it is under investigation by the ACCC concerning its subscription offerings, signaling potential regulatory scrutiny for the property tech giant.

TerraCom Limited has reached a significant settlement with ASIC to resolve whistleblower-related civil proceedings, agreeing to pay $8.5 million pending Federal Court approval.

Wellnex Life Limited’s shares have been suspended from trading on the ASX pending a response to regulatory queries, stirring investor uncertainty.

ALS Limited delivered a robust FY25 performance with 16% revenue growth to $3 billion and underlying EBIT rising 4.7% to $515 million, driven by strong organic growth and strategic acquisitions. The company is advancing its Nuvisan integration ahead of schedule and has unveiled a $230 million investment plan to expand key laboratories, positioning itself for sustained growth amid market uncertainties.

Cash Converters has announced its exit from the Small Amount Credit Contract payday lending sector, signaling a strategic shift away from this controversial market segment.

Mayne Pharma has clarified why it did not disclose an FDA Untitled Letter to the market despite sharing it with its scheme bidder, reaffirming compliance with ASX rules amid recent share price volatility.